Welcome to LookChem.com Sign In|Join Free

CAS

  • or

130676-66-3

Post Buying Request

130676-66-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (2S,3S,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic Acid

    Cas No: 130676-66-3

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

130676-66-3 Usage

Description

(2S,3S,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic Acid (Orlistat Impurity) is a degradation product of Tetrahydrolipstatin (Orlistat), which is a pharmaceutical compound used as a lipase inhibitor for the treatment of obesity. This impurity is formed through the thermal and hydrolytic degradation of Orlistat and is also identified as a metabolite of Orlistat (O686500). It exhibits chemical properties of a clear light yellow viscous oil.

Uses

Used in Pharmaceutical Industry:
(2S,3S,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic Acid (Orlistat Impurity) is used as a research compound for understanding the degradation pathways and metabolic processes of Orlistat. This knowledge aids in the development of more stable formulations and the optimization of drug delivery systems, ultimately enhancing the safety and efficacy of Orlistat as a treatment for obesity.
Used in Quality Control and Regulatory Compliance:
As an Orlistat impurity, (2S,3S,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic Acid plays a role in the quality control and regulatory compliance of Orlistat products. It is essential to monitor and control the levels of this impurity in the final drug product to ensure patient safety and meet regulatory standards.
Used in Drug Metabolism Studies:
This Orlistat impurity is also utilized in drug metabolism studies to investigate how Orlistat is processed and eliminated from the body. Understanding the metabolic pathways and the formation of this impurity can provide insights into the pharmacokinetics and pharmacodynamics of Orlistat, which can be valuable for the development of new drugs or the improvement of existing ones.

Check Digit Verification of cas no

The CAS Registry Mumber 130676-66-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,6,7 and 6 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 130676-66:
(8*1)+(7*3)+(6*0)+(5*6)+(4*7)+(3*6)+(2*6)+(1*6)=123
123 % 10 = 3
So 130676-66-3 is a valid CAS Registry Number.
InChI:InChI=1/C29H55NO6/c1-5-7-9-11-12-13-14-15-16-18-24(36-29(35)26(30-22-31)20-23(3)4)21-27(32)25(28(33)34)19-17-10-8-6-2/h22-27,32H,5-21H2,1-4H3,(H,30,31)(H,33,34)/t24-,25-,26?,27-/m0/s1

130676-66-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S,3S,5S)-5-[[(S)-2-(Formylamino)-4-methylpentanoyl]oxy]-2-hexyl-3-hydroxyhexadecanoic Acid

1.2 Other means of identification

Product number -
Other names (2S,3S,5S)-5-{[(S)-2-(Formylamino)-4-methylpentanoyl]oxy}-2-hexyl-3-hydroxyhexadecanoic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:130676-66-3 SDS

130676-66-3Downstream Products

130676-66-3Relevant articles and documents

Tetrahydrolipstatin: Thermal and hydrolytic degradation

Stalder,Schneider,Oesterhelt

, p. 1022 - 1036 (2007/10/02)

The thermal and hydrolytic degradation of tetrahydrolipstatin (THL, 1) was investigated. All main degradation products were isolated, characterized, and synthesized. Labile intermediates unavailable to isolation were detected and identified by GC/MS analysis of their silylated derivatives, and whenever possible, compared with independently prepared reference compounds. The identified degradation products represent at least 97% of the total degradation mixture. Two main reaction pathways are proposed. Pharmacological data are reported for the degradation mixture and the main degradation products.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 130676-66-3